Catamaran Corp (CTRX): Today's Featured Health Services Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Catamaran ( CTRX) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole closed the day up 0.4%. By the end of trading, Catamaran fell $0.85 (-1.5%) to $55.33 on light volume. Throughout the day, 815,498 shares of Catamaran exchanged hands as compared to its average daily volume of 1,763,800 shares. The stock ranged in price between $55.22-$56.19 after having opened the day at $56.12 as compared to the previous trading day's close of $56.18. Other companies within the Health Services industry that declined today were: Escalon Medical Corporation ( ESMC), down 6.1%, IsoRay ( ISR), down 5.2%, Stereotaxis ( STXS), down 5.0% and Daxor Corporation ( DXR), down 4.7%.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $11.5 billion and is part of the health care sector. Shares are up 18.1% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Catamaran a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, compelling growth in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, Response Genetics ( RGDX), up 27.1%, Spherix ( SPEX), up 22.4%, Uroplasty ( UPI), up 8.0% and ZELTIQ Aesthetics ( ZLTQ), up 7.9% , were all gainers within the health services industry with Boston Scientific ( BSX) being today's featured health services industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Stocks Tumble as Trump Comments Lead to Worries Over China Trade Talks

Tiffany & Co. Sees a Strong Market in Asia

Tiffany & Co. Sees a Strong Market in Asia

Imagining the Stock Market in 10 Years

Imagining the Stock Market in 10 Years

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Video: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific